Summit Therapeutics PLC (SMMT)
Stock Price:
$4.70 USD
-0.01 (-0.21%)
Updated December 3, 9:47 AM EST - Market open
Key Info
| Market Cap |
315.99M |
| Revenue (ttm) |
22.09M |
| Net Income (ttm) |
-50.29M |
| Shares Out |
335.89M |
| EPS (ttm) |
-0.26 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 3 |
| Last Price |
$4.70 |
| Previous Close |
$4.71 |
| Change ($) |
-0.01 |
| Change (%) |
-0.21% |
| Day's Open |
4.74 |
| Day's Range |
4.68 - 4.74 |
| Day's Volume |
9,199 |
| 52-Week Range |
3.25 - 4.91 |
More Stats
| Market Cap |
315.99M |
| Enterprise Value |
295.27M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
335.89M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.26 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
57,968 |
| Short Ratio |
0.44 |
| Short % of Float |
n/a |
| Beta |
0.59 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
14.30 |
| PB Ratio |
10.69 |
| Revenue |
22.09M |
| Operating Income |
n/a |
| Net Income |
-50.29M |
| Free Cash Flow |
n/a |
| Net Cash |
20.72M |
| Net Cash / Share |
0.31 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-36.13% |
| ROE |
n/a |
| ROIC |
n/a |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
0 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Low
4.00
Current: $4.70
High
4.00
Target: 4.00
*Average 12-month USD price target from 1 stock analysts.
Financial Performance
Financial numbers in millions GBP.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | 53.77 | 15.45 | 2.88 | - | - | - | - |
| Revenue Growth | - | 247.99% | 436.46% | - | - | - | - | - |
| Gross Profit | - | 53.77 | 15.45 | 2.88 | - | - | - | - |
| Operating Income | - | 3.34 | -32.29 | -31.07 | -25.43 | -15.29 | -8.39 | -5.72 |
| Net Income | - | 9.36 | -25.20 | -26.71 | -25.17 | -14.23 | -7.62 | -5.28 |
| Shares Outstanding | 160 | 73.56 | 61.84 | 61.29 | 41.12 | 58.37 | 58.37 | - |
| Earnings Per Share | - | 0.11 | -0.39 | -0.44 | -0.43 | -0.36 | -0.38 | -0.34 |
| Operating Cash Flow | -25.98 | -33.33 | -18.18 | 15.18 | -21.48 | -14.58 | -7.34 | -3.98 |
| Capital Expenditures | -0.27 | -0.15 | -0.45 | -0.10 | -0.08 | -0.04 | 0.08 | -0.04 |
| Free Cash Flow | -26.25 | -33.48 | -18.63 | 15.08 | -21.56 | -14.63 | -7.26 | -4.03 |
| Cash & Equivalents | 63.84 | 33.57 | 25.13 | 35.08 | 20.38 | 14.08 | 2.54 | - |
| Total Debt | 0.89 | 1.26 | 5.47 | 7.40 | 6.29 | 2.69 | - | - |
| Net Cash / Debt | 62.95 | 32.32 | 19.66 | 27.68 | 14.09 | 11.39 | 2.54 | - |
| Assets | 96.68 | 75.79 | 68.97 | 46.98 | 31.32 | 24.25 | 9.12 | - |
| Liabilities | 19.44 | 22.62 | 72.91 | 51.35 | 11.22 | 8.04 | 3.17 | - |
| Book Value | 77.24 | 53.17 | -3.94 | -4.37 | 20.10 | 16.20 | 5.95 | - |
Numbers in millions GBP, except per-share numbers.
Company Details
| Full Name |
Summit Therapeutics PLC |
| Employees |
70 |
Stock Information
| Ticker Symbol |
SMMT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SMMT |
Description
Summit Therapeutics, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. Summit Therapeutics Inc. was founded in 2003 and is based in Cambridge, Massachusetts.